Pharmacologie des thérapeutiques ciblées.

A better understanding of oncogenesis has allowed potential therapy targets to be identified in recent years. This has resulted in the development of more specific medicines for molecular disorders that cause tumours or molecular disorders involved in tumour progression. These are known as targeted therapies. These new therapies inhibit cell growth and are described as cytostatic. These are two types: monoclonal antibodies that target EGFR receptors and tyrosine kinase inhibitors. They can be used alone or in combination with conventional chemotherapy and mean that much more specific treatments can be offered that are truly efficacious and have favourable toxicity profiles. [ABSTRACT FROM AUTHOR]